Navigation Links
Brain tumors: New therapy surprisingly successful
Date:3/6/2009

This release is available in German.

The combination of two drugs produces a critical improvement in the treatment of certain brain tumours. This has been demonstrated by researchers at Bonn University working in co-operation with German and Swiss colleagues in a current study. They treated 39 patients who had been diagnosed with a so-called gliablastoma. The patients survived on average 23 months; with the standard therapy the mean would have been 14.6 months. Glioblastomas are the most aggressive and the commonest brain tumours. Left untreated, they prove fatal within just a few weeks. The study has been published in the Journal of Clinical Oncology (doi: 10.1200/JCO.2008.19.2195).

Even today, glioblastomas are untreatable something which even the new combination therapy cannot change. Nevertheless, Professor Dr. Ulrich Herrlinger of Bonn Universitys Schwerpunkt Klinische Neuroonkologie speaks of an outstanding success: "This unusually manifest extension of the survival time has surprised even us. Our results offer the opportunity to improve our grip on this aggressive form of cancer. Now, further investigations involving a larger number of patients are needed to optimise this therapy. Planning for this is already in hand in Bonn".

Up to now, doctors have treated glioblastomas using radiotherapy with concomitant chemotherapy. The "gold standard" for this for the last few years has been the active agent temozolomide. This is still celebrated as the most important breakthrough in the treatment of glioblastomas. The researchers combined this preparation with the drug lomustine. At the same time, the patients were given radiotherapy. The 39 patients thus treated survived the tumour for an average of 23.1 months. With the standard therapy, this time is over one third shorter. Seven patients even survived for over four years.

Genes decide the Success of the Therapy

It would appear that certain changes in the genotype are critical for the success of this therapy. "With eleven participants in the study, the information of one gene had been subjected to a characteristic modification", Ulrich Herrlinger declares. "These patients survived on average a good 34 months. With the other patients, these drugs appeared to bring no apparent advantage vis--vis pure radiotherapy at least, not in the dosage we tested. It is possible that a simple gene test could decide for whom a concomitant chemotherapy might be of benefit". One disadvantage of the new method are the side-effects. However, these mostly occur during the several months of the treatment phase. "After that they normally disappear completely, and the patients have no further complaints about them", Herrlinger stresses.

Working in co-operation with the Life&Brain-Zentrum in Bonn, the search is now on for more compatible, more effective, drugs. "Amongst other things, we now want to use cell cultures from original tumours to study precisely what the preparations we used in the study really effect", Dr. Martin Glas, one of the authors of the study, declares.


'/>"/>

Contact: Dr. Ulrich Herrlinger
Ulrich.Herrlinger@ukb.uni-bonn.de
49-228-287-19887
University of Bonn
Source:Eurekalert

Related medicine news :

1. Brain Tumor Drug May Help Spur Cancers Return
2. Brain tumor treatment may increase number of cancer stem-like cells
3. European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors
4. Now Hear This: Brain Fitness Exercises Improve Listening
5. Nearly 1.4 Million Sustain Traumatic Brain Injuries Each Year
6. National Council on Disability Says More Needs to be Done for Service Members and Veterans With Post Traumatic Stress Disorder and Traumatic Brain Injury
7. Brain Adapts to Age-Related Eye Disease
8. UCI scientists to study brain region linked to autism, schizophrenia
9. Schizophrenia linked to signaling problems in new brain study
10. ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinsons Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinsons Brain
11. Sex is in the brain, says new research from Stanford
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s recent feature in ... Along with performing procedures, the magazine also highlights that Dr. Sadati has pioneered ... of the most common procedures he performs is his natural facelift. “As people ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... The president ... DoD Military Health System but would shift more of the cost burden to military ... TRICARE-reform plan laid out in the defense budget as including limited quantifiable benefit fixes ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... and women’s health, is pleased to announce the promotions of Allison Kelly to ... team, Steve Catone to executive vice president of North American capital sales, and ...
(Date:2/11/2016)... Laurel, NJ (PRWEB) , ... February 11, 2016 ... ... announces the call for nominations seeking candidates for the Board of Commissioners. Individuals ... with passion, skills and experience with diversity of clinical practice settings and across ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... of a master charity program created to assist the people of their local ... closely with nonprofit organizations and community leaders. Their hope is to bring awareness ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016   ... the advancement of new health technologies, announced today " ... outstanding achievements in health tech over the past ten ... For nearly a decade, Health 2.0 has served ... and showcased and connected with thousands of technologies, companies, ...
(Date:2/11/2016)... 11, 2016  MiMedx Group, Inc. (NASDAQ: MDXG ... membrane and other birth tissues, human skin and bone, ... market advanced products and therapies, announced today that it ... Healthcare Conference in New York , ... Michael J. Senken , Chief Financial Officer and ...
Breaking Medicine Technology: